HENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend

Bulletin Express03-11

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai.

The agenda includes:

1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025. 2. Considering the declaration and payment of a final dividend, if any.

Chairman Sun Piaoyang issued the notice on 11 March 2026. The current Board comprises:

• Executive Directors: Sun Piaoyang, Dai Hongbin, Feng Ji, Zhang Lianshan, Jiang Frank Ningjun, and Sun Jieping. • Non-executive Director: Guo Congzhao. • Independent Non-executive Directors: Dong Jiahong, Zeng Qingsheng, Sun Jinyun, and Chow Kyan Mervyn.

The company will publish the audited results following the Board’s approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190125604?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190125604","market":"us","top_or_hot":-1,"title":"HENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend","media":"Bulletin Express","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai.</p>\n<p>The agenda includes:</p>\n<p>1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Considering the declaration and payment of a final dividend, if any.</p>\n<p>Chairman Sun Piaoyang issued the notice on 11 March 2026. The current Board comprises:</p>\n<p>• Executive Directors: Sun Piaoyang, Dai Hongbin, Feng Ji, Zhang Lianshan, Jiang Frank Ningjun, and Sun Jieping.  \n• Non-executive Director: Guo Congzhao.  \n• Independent Non-executive Directors: Dong Jiahong, Zeng Qingsheng, Sun Jinyun, and Chow Kyan Mervyn.</p>\n<p>The company will publish the audited results following the Board’s approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-11 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai.</p>\n<p>The agenda includes:</p>\n<p>1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Considering the declaration and payment of a final dividend, if any.</p>\n<p>Chairman Sun Piaoyang issued the notice on 11 March 2026. The current Board comprises:</p>\n<p>• Executive Directors: Sun Piaoyang, Dai Hongbin, Feng Ji, Zhang Lianshan, Jiang Frank Ningjun, and Sun Jieping.  \n• Non-executive Director: Guo Congzhao.  \n• Independent Non-executive Directors: Dong Jiahong, Zeng Qingsheng, Sun Jinyun, and Chow Kyan Mervyn.</p>\n<p>The company will publish the audited results following the Board’s approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1190125604","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190125604","pubTimestamp":1773218617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai. The agenda includes: 1. Reviewing and approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"恒瑞医药(01276)定于2026年3月25日召开董事会批准2025财年业绩及末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai.\nThe agenda includes:\n1. Reviewing and approving the consolidated annual results for the financial year ended 31 December 2025.  \n2. Considering the declaration and payment of a final dividend, if any.\nChairman Sun Piaoyang issued the notice on 11 March 2026. The current Board comprises:\n• Executive Directors: Sun Piaoyang, Dai Hongbin, Feng Ji, Zhang Lianshan, Jiang Frank Ningjun, and Sun Jieping.  \n• Non-executive Director: Guo Congzhao.  \n• Independent Non-executive Directors: Dong Jiahong, Zeng Qingsheng, Sun Jinyun, and Chow Kyan Mervyn.\nThe company will publish the audited results following the Board’s approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190125604","isCrawlerRequest":true}